Robertson GL. Diabetes insipidus: Differential diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):205-18. doi: 10.1016/j.beem.2016.02.007. Epub 2016 Feb 18. Review. PMID: 27156759.
Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol. 2015 Oct;11(10):576-88. doi: 10.1038/nrneph.2015.89. Epub 2015 Jun 16. Review. PMID: 26077742.
Emma F, Nesterova G, Langman C, et al. Nephropathic cystinosis: an international consensus document. Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv87-94. doi: 10.1093/ndt/gfu090. PMID: 25165189; PMCID: PMC4158338.
Both T, Zietse R, Hoorn EJ, et al. Everything you need to know about distal renal tubular acidosis in autoimmune disease. Rheumatol Int. 2014 Aug;34(8):1037-45. doi: 10.1007/s00296-014-2993-3. Epub 2014 Mar 29. Review. PMID: 24682397; PMCID: PMC4107275.
Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant. 2012 Dec;27(12):4273-87. doi: 10.1093/ndt/gfs493. Review. PMID: 23235953; PMCID: PMC3616759.
Reddy P. Clinical approach to renal tubular acidosis in adult patients. Int J Clin Pract. 2011 Mar;65(3):350-60. doi: 10.1111/j.1742-1241.2009.02311.x. Review. PMID: 21314872.
Landau D. Potassium-related inherited tubulopathies. Cell Mol Life Sci. 2006 Sep;63(17):1962-8. Review. PMID: 16810456.
Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002 Aug;13(8):2160-70. Review. PMID: 12138150.
Shaer AJ. Inherited primary renal tubular hypokalemic alkalosis: a review of Gitelman and Bartter syndromes. Am J Med Sci. 2001 Dec;322(6):316-32. Review. PMID: 11780689.
Definition and EtiologyTop
Proximal renal tubular acidosis (pRTA), also known as type 2 renal tubular acidosis, can occur as an isolated defect in bicarbonate reabsorption or in association with other defects in proximal tubular function, leading to impaired reabsorption of other solutes, such as phosphate, glucose, uric acid, and amino acids. These patients usually have an isolated non–anion gap acidosis.
If acidosis develops in association with loss of other solutes, the patient may have hypophosphatemia, hypouricemia, renal glycosuria (with normal serum glucose concentrations), and/or aminoaciduria; this is termed Fanconi syndrome.
Isolated hereditary pRTA is rare and can be autosomal dominant or autosomal recessive. Rare sporadic cases have been reported. Acetazolamide and topiramate are two commonly reported drugs also known to cause isolated pRTA.
More commonly pRTA is found in conjunction with Fanconi syndrome, which may be caused by several genetic and acquired systemic diseases. Etiologies of pRTA and Fanconi syndrome: Table 1.
DiagnosisTop
Patients with pRTA develop an increase in their urinary pH following an alkali load. Their urine pH may rise from 5.5 at baseline to 7.5 when serum bicarbonate levels are normalized following the administration of sodium bicarbonate.
TreatmentTop
If renal tubular acidosis (RTA) persists following treatment of the underlying cause, it can be managed with supplemental doses of alkali therapy.
Treatment of patients with pRTA requires treatment of acidemia and rarely of hypokalemia and hypophosphatemia. Compared with patients with distal RTA, the requirement for alkali therapy is usually significantly higher (up to 10-15 mEq/kg/d) to exceed the urinary bicarbonate losses (although doses of about 2 mEq/kg/d may be sufficient, with 100 mEq translating into 8.4 g of oral sodium bicarbonate). This can be done with sodium bicarbonate, sodium citrate, or potassium citrate. It is not uncommon to use a combination of potassium-based and sodium-based alkali to ensure potassium replacement and compensate for the urinary potassium losses. These losses are related to increased water and salt delivery to the distal tubule and negatively charged urinary bicarbonate ions stimulating secretion of potassium into urine. Thiazide diuretics may be occasionally used, as inducing mild volume depletion leads to increased proximal sodium and bicarbonate reabsorption.
TablesTop
Familial |
Cystinosisa, Wilson disease, hereditary fructose intolerance, tyrosinemia, galactosemia, Lowe disease, Dent disease |
Dysproteinemias |
Multiple myeloma (LCDD)a, amyloidosis |
Drugs |
Acetazolamidea, topiramate, NRTIs (tenofovira, adefovir, didanosine, lamivudine), chemotherapeutics (ifosfamide, platinum-based chemotherapy) |
Heavy metals |
Leada, mercury, copper (Wilson disease) |
Tubulointerstitial diseases |
Renal transplant, Balkan/Chinese herb nephropathy (aristolochic acid toxicity), medullary cystic kidney disease |
Other |
Vitamin D deficiency |
Familial causes are more prevalent among the pediatric population but can remain undiagnosed until later in life. | |
a The more common etiologies. | |
LCDD, light chain deposition disease; NRTI, nucleoside reverse transcriptase inhibitor. |